全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Khurum H. Khan , Montserrat Blanco-Codesido , L. Rhoda Molife
来源:[J].Critical Reviews in Oncology / Hematology(IF 4.637), 2014, Vol.90 (3), pp.200-219Elsevier
摘要:Abstract(#br)Apoptosis, a physiological process of programmed cell death, is disrupted in various malignancies. It has been exploited as an anti-cancer strategy traditionally by inducing DNA damage with chemotherapy and radiotherapy. With an increased understanding of the intrins...
作者:L. Rhoda Molife , Rebecca Kristeleit ...
来源:[J].Clinical Therapeutics(IF 2.23), 2016, Vol.38 (10), pp.2286-2299Elsevier
摘要:Abstract(#br)Purpose(#br)The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA -mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We assessed the pote...
作者:L. Rhoda Molife , Udai Banerji ...
来源:[J].Gastric Cancer(IF 3.989), 2014, Vol.17 (4), pp.621-629Springer
摘要:Abstract(#br) Background(#br)Conventional therapeutic options for patients with advanced upper gastrointestinal cancers (UGIC) are limited. Following first-line treatments, some patients are offered experimental therapies, including participation in Phase I trials. This stud...
作者:L. Rhoda Molife , Jan H. M. Schellens ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2019, Vol.58 (9), pp.1165-1174Springer
摘要:Abstract(#br) Background(#br)Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.(#br) Me...
作者:... Karen So , Wendy Bannister , L. Rhoda Molife
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2015, Vol.76 (4), pp.723-729Springer
摘要:Abstract(#br) Background(#br)The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA -mutated cancer. This Phase I, open-label, three-part study (Parts A–C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of...
作者:L. Rhoda Molife , Sarah M. Rudman ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2013, Vol.72 (6), pp.1213-1222Springer
摘要:Abstract(#br) Purpose(#br)Afatinib is an irreversible ErbB family blocker currently under evaluation in late-stage clinical trials. This study primarily assessed the cardiac safety, pharmacokinetics and antitumor activity of afatinib in cancer patients.(#br) Methods(#br)In t...
作者:... Jesus Corral , L. Rhoda Molife , Johann S. Bono
来源:[J].Current Oncology Reports(IF 3.327), 2012, Vol.14 (2), pp.111-119Springer
摘要:Abstract(#br)The fibroblast growth factor (FGF) signaling pathway is implicated as a key driver of tumor progression and growth via the dysregulation of cell proliferation, differentiation, survival, and angiogenesis in multiple tumor types. In addition, it may serve as a mechani...
作者:L. Rhoda Molife , Udai Banerji ...
来源:[J].European Journal of Cancer(IF 5.061), 2010, Vol.46 (15), pp.2739-2745Elsevier
摘要:Abstract(#br)Background(#br)Unplanned hospital admissions (UHAs) in the context of oncology Phase I trials are important, yet rarely reported.(#br)Methods(#br)All patients admitted to the Royal Marsden Hospital Phase I clinical trials unit during February and March of 2005–2...
作者:L. Rhoda Molife , Samreen Ahmed ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2009, Vol.64 (2), pp.425-429Springer
摘要:Abstract(#br) Purpose(#br)The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI ™ ) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 1...
作者:L. Rhoda Molife , Stan B. Kaye ...
来源:[J].PLOS ONE(IF 3.73), 2012, Vol.7 (11)PLOS
摘要:Tumor genomic instability and selective treatment pressures result in clonal disease evolution; molecular stratification for molecularly targeted drug administration requires repeated access to tumor DNA. We hypothesized that circulating plasma DNA (cpDNA) in advanced cancer...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×